{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2019"],"data_sharing_plan":["IPD Sharing (as of May 2022): No"],"condition":["Pseudomyxoma Peritonei","Peritoneal Cancer","Cystadenocarcinoma","Mucinous Adenocarcinoma","Mucinous Tumor","Gastric Cancer","Colorectal Cancer","Primary Peritoneal Carcinoma","Mesothelioma","Adenocarcinoma, Mucinous"],"disease":["Pseudomyxoma Peritonei","Peritoneal Cancer","Cystadenocarcinoma","Mucinous Adenocarcinoma","Mucinous Tumor","Gastric Cancer","Colorectal Cancer","Primary Peritoneal Carcinoma","Mesothelioma","Adenocarcinoma, Mucinous"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2316218"],"location":["United States"],"study_start_month":["10"],"keyword":["Irinotecan","HIPEC","Nal-irinotecan"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase I Trial HIPEC With Nal-irinotecan","description":"The purpose of this study is to assess the effectiveness and safety of intraperitoneal administration of heated nanoliposomal Irinotecan in cytoreductive surgery (CRS), which is surgery designed to remove as much of the cancer as possible, and heated intraperitoneal chemotherapy (HIPEC) procedures.","dates":{"creation":"2019-10-15"},"accession":"2316218","cross_references":{"ClinicalTrials___gov":["NCT04088786"]}}